- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02506179
Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis (UCanADA)
January 22, 2021 updated by: AbbVie
A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)
To evaluate the real-life effect after 1 year of adalimumab treatment on psychological distress/depression symptoms in moderate-to-severe Ulcerative Colitis (UC) patients.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 4Z6
- University of Calgary /ID# 144032
-
Edmonton, Alberta, Canada, T6G 2X8
- Zeidler Ledcor Centre /ID# 145973
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W5
- Columbia Gastro Mgmnt Ltd /ID# 136820
-
Vancouver, British Columbia, Canada, V6Z 2K5
- GIRI Gastrointestinal Research Institute /ID# 141107
-
Victoria, British Columbia, Canada, V8T 5G4
- Discovery Clinical Services /ID# 144102
-
Victoria, British Columbia, Canada, V8V 3M9
- Percuro Clinical Research, Ltd /ID# 136533
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B 5N5
- Dr. Everett Chalmers Reg Hosp. /ID# 136534
-
St. John, New Brunswick, Canada, E2K 1J5
- Dr Chadwick Ian Williams Professional Corporation /ID# 144802
-
-
Ontario
-
Brampton, Ontario, Canada, L6S 0C1
- Bellini Medicine Professional /ID# 144241
-
Oshawa, Ontario, Canada, L1H 1B9
- Oshawa Clinic /ID# 144364
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital /ID# 139392
-
Toronto, Ontario, Canada, M53 TA9
- Kensington Screening Clinic /ID# 141106
-
Toronto, Ontario, Canada, M5G 1X5
- Mount Sinai Hosp.-Toronto /ID# 141108
-
Windsor, Ontario, Canada, N8W 1E6
- Dr O Tarabain Medicine Prof Corp /ID# 144034
-
Windsor, Ontario, Canada, N8Y 4C9
- Dr. Rahman Bacchus Med. Corp. /ID# 141780
-
-
Quebec
-
Levis, Quebec, Canada, G6V 3Z1
- Hopital Hotel-Dieu de Levis /ID# 137099
-
Montreal, Quebec, Canada, H1T 2M4
- Hospital Maisonneuve-Rosemont /ID# 137336
-
Montreal, Quebec, Canada, H2X 3J4
- CHUM - Hopital Saint-Luc /ID# 139393
-
Montreal, Quebec, Canada, H3G 1A4
- McGill Univ HC /ID# 136821
-
Montreal, Quebec, Canada, H3P 3E5
- Clinique MEDI-CLE /ID# 153690
-
Quebec City, Quebec, Canada, G1R 2J6
- CHU de Quebec-Universite Laval /ID# 147557
-
Sherbrooke, Quebec, Canada, J1H 5N4
- CHUS - Hopital Fleurimont /ID# 137840
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Royal Univ. Hosp, Saskatoon,CA /ID# 137838
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult males and females with moderate to severe UC patients from Canada who meet the inclusion criteria and who do not meet any of the exclusion criteria will be eligible for enrollment into the study.
Description
Inclusion Criteria:
- Patient must voluntarily sign and date a patient authorization.
- Patient must be ≥ 18 years of age.
- Patient must have confirmed diagnosis of UC.
Patient must have:
- a Mayo endoscopic sub score of 2 or 3 from endoscopic investigation in the previous 3-months that is closest to the baseline visit or
- a Mayo rectal bleeding subscore ≥ 2 and a calprotectin value greater than 250 µg/gr.
- Patient must have been prescribed adalimumab as part of his treatment by his treating physician.
- If the patient was previously treated with vedolizumab or any anti-TNF agent (except adalimumab), an appropriate washout has taken place as per routine practice.
Exclusion Criteria:
- Patient has previously received adalimumab.
- Patient has previously used infliximab or any anti-TNF agent and have not clinically responded at any time ("primary non-responder") unless they experienced a treatment limiting reaction.
- Patient with a history of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for UC or planned bowel surgery.
- Patient with a current diagnosis of indeterminate colitis, ulcerative proctitis only, or with a current diagnosis and/or have a history of Crohn's disease.
- Patient with other tumor necrosis factor (TNF) immune-modulated disease.
- Patient has a significant history of renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, cardiovascular, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
- A female patient is pregnant or breast-feeding.
- Patient is currently participating in another prospective study including controlled clinical trials and observational studies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Open-label cohort
Patients will be followed for 52 weeks post initiation of adalimumab (Week 0).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in depressive symptoms at Week 52
Time Frame: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the Patient Health Questionnaire - 9 Items (PHQ-9).
|
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in depressive symptoms at Week 8
Time Frame: From Week 0 to Week 8, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the Patient Health Questionnaire - 9 Items (PHQ-9).
|
From Week 0 to Week 8, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in the proportion of patients with PHQ-9 >= 10
Time Frame: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
The change from baseline in the proportion of patients with PHQ-9 >= 10 is assessed at week 8 and 52.
|
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Disability
Time Frame: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the Inflammatory Bowel Disease (IBD) Disability Index at weeks 8 and 52.
|
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Overall quality of life
Time Frame: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the EuroQol 5-Dimensions, 5 Levels (EQ-5D-5L) and EQ5D VAS at weeks 8 and 52.
|
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Ulcerative Colitis (UC)-specific quality of life
Time Frame: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the Short Quality of Life in Inflammatory Bowel Disease Questionnaire (SIBDQ) at weeks 8 and 52.
|
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Fatigue
Time Frame: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the Functional Assessment Chronic Illness Therapy-Fatigue (FACIT-F) at weeks 8 and 52.
|
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Sleep impairment,
Time Frame: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
It is measured by the Medical Outcomes Study Sleep scale (MOS Sleep) at weeks 8 and 52.
|
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Work productivity
Time Frame: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
The change from baseline in work productivity is assessed at week 8 and 52.
|
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Assessing Simple Clinical Colitis Activity Index (SCCAI)
Time Frame: Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
SCCAI is used to access response and remission rates.
|
Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Fecal Calprotectin levels
Time Frame: From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
The change from baseline in Fecal Calprotectin levels will be assessed.
|
From Week 0 to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Mayo endoscopic sub-score
Time Frame: Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Mayo endoscopic sub-score will be assessed.
|
Up to Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Proportion of patients with Complications including hospitalization and surgery
Time Frame: At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
The proportion of patients with complications including hospitalization and surgery will be assessed.
|
At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Proportion of patients on steroids
Time Frame: At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
The proportion of patients on steroids will be assessed.
|
At Week 52, or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Change from baseline in Physician's Global Assessment (PGA)
Time Frame: From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
The change from baseline in Physician's Global Assessment (PGA) will be assessed.
|
From Week 0 to Week 52 or at the time of stopping adalimumab, or at the time of Premature Discontinuation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 18, 2015
Primary Completion (Actual)
February 10, 2020
Study Completion (Actual)
February 10, 2020
Study Registration Dates
First Submitted
June 26, 2015
First Submitted That Met QC Criteria
July 21, 2015
First Posted (Estimate)
July 23, 2015
Study Record Updates
Last Update Posted (Actual)
January 25, 2021
Last Update Submitted That Met QC Criteria
January 22, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P15-325
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael